AI Article Synopsis
- Glucagonoma is a rare type of pancreatic tumor that leads to overproduction of glucagon and is associated with symptoms like necrolytic migratory erythema.
- First-line treatments include surgery and somatostatin analogs, while radioligand therapy with [177Lu]Lu-DOTA-TATE is used as a second-line option for advanced cases.
- This text discusses a unique case of a metastatic glucagonoma successfully treated with [177Lu]Lu-DOTA-TATE when the disease progressed.
Article Abstract
Glucagonoma is a rare pancreatic neuroendocrine tumor (panNET) that can be characterized by increased secretion of glucagon and distinguishing symptoms - glucagonoma syndrome with a typical dermatosis, necrolytic migratory erythema, being its most common manifestation. While surgery and somatostatin analogs remain first-line therapeutic options in panNETs, radioligand therapy with [177Lu]Lu-DOTA-TATE is a recommended second-line palliative treatment in advanced, metastatic cases. However, its prospects and efficacy are still not vastly researched in less frequent neuroendocrine neoplasms. Here, we present an extraordinary case of a metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE used as a second-line treatment in progressive disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5603/nmr.101985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!